20 million pounds in 2013
70 million pounds in 2018
Do you know rough PHA price per pound?
Hopefully, Shaw will not think same as you, otherwise there will not be settlement or buyout. There is much more to a success or failure of a marketing strategy than what BD has been charged with. I think RVP failed and will fail in future to gain much market traction, even if there is some settlement to open doors. BDX is a much better run company with far more capital and reach and will squash RVP even on equal footing basis (unless RVP can come up with a new revolutionary product)
It is wise for RVP not to play the hand you talked about too much ..i.e. if on equal footing, I will be much bigger player .. If they want to do that, I will sell all my shares immediately after a settlement is announced as i am fairly certain they will fail again.
But, to the extent the settlement results in other (non-RVP) players to gain better access to market, BDX sales could hurt materially. To avoid this threat, a settlement and buyout is in BDX favor.
I am fairly certain BDX judgment is what is best for biz and that means they buyout RVP.
A price of $12 a share is reasonable for both parties. I doubt RVP could reach $12 if it wants to use proceeds from settlement to gain material market shares and profitability by eating BDX and other competitors. BDX has a significant biz interest in this settlement does not result in opening doors to other competitors gaining better access to hospital market.
The fact that it has taken this long to reach something tells me that they are trying really hard and hopefully they are in last stages as opposed to gridlock
For now, ignore tax effects
1- BD pays $250M to settle lawsuit
So, RVP has $175M more cash (after deducting lawyers fees)
2- BD then immediately offers $12 a share (i.e. net of RVP cash, pays $125M)
So, BD pays $250 + $125 = $375M to own RVP and lawsuit gone, shareholders get $12 and RVP lawyer gets $75M
*** Tax implications are important which above does not take into account and also the exact RVP legal fees
Above deal structure allows
- separation of settlement from acquisition
- allows maximum RVP shareholder value
- signals to market that BDX does not overpay for settlement
-- limits a cap for lawyer fees.
The breakup fee is so RVP does not get screwed by BDX, while the acquisition passes necessary steps
these are all my dream speculation
just wanted to know if MT stands for million ton, so 1MT=1 billion kg ??
Also, if 2013 is 10,000 MT who is supplying it as mblx contribution is zero
is that 34,000 million ton or 34 billion kg ?? Am I reading this right?
to quell rumors that $6.5 was inflated price by the secondary guys
Buyer will get the pipeline for $300M ... maybe it will be J&J since its dox patents are going away
1- CEO and some management to step down
2- Sell the company
They say the $2 cash might be at risk as those that bought at $6.5 say they were misled. LoL .. Over past 20 years I have invested, I have never seen privil clients get their money back in a secondary offering that went sour ... CYTR has $120M cash Aand market cap of $250M
1-over 100M cash
2-market cap of about $200M
3- A drug that fda allowed them to keep dosing until PFS stops !! this is big
Following deal will be announced
Full Settlement for $250M and at same time acquisition at $12 a share and if for any reason sales falls through, a break up fee of $100M
This will cap RVP lawyer's fee to 30% of $250M and we get $12 a share
above is pure speculation on my side ... I think above deal structures allows maximum RVP shareholder benefit, appearance that sale was not part of settlement, protects RVP if BDX backs off from deal, and puts RVP litigation cost to a defined limit.
i welcome others suggestions
they have over $100M cash and 50 million shares or about $200M market cap
what a gift .. I don't care about lawsuit. What I care about is cash, debt, the drug's chance of success, drugs sales potential and patents protecting sales
warrant holders do what is best for stock price because warrant holders are also shareholders. It is better for stock to do cashless as less stock is sold to public. Cash injected at $2.5 can always be injected at less dilution.
If warrants holder decide to cash out 100%, then they still prefer cashless
Either way you look at, it will be cashless, unless thye want to exercise and hold for long term which I doubt
is about 15 million (most likely all warrants will be exercised cashless) .. so about 3 times float already traded !!!!
earnings is expected to be bad due to lira .. outlook should get progressively better in 2014-2020 .. so, these are bottom prices, i think
-- around 85% of revenue is recurring
-- Short listed on several $10M a year bids ...
My take is each win could add $5M / year to bottom line (I think each win could pop pps by $5 a share)
-- they also said integration of OTI went quite well